TechKnow Invest Roadshow: Alcidion (ASX:ALC) Presenting

Company Name: Alcidion

Announcement Date: 14/10/2016
Announcement Category: Other
Announcement Content:

Alcidion are presenting at the upcoming October TechKnow Invest Roadshow event next week, in Melbourne, Sydney and Brisbane.

Executive Vice President, Nathan Buzza will be presenting Alcidion and it is an excellent opportunity to hear the key highlights from FY16 and learn about our milestone targets for FY17. Including;

Preparation beginning for a planned move into North America by 2018.
Deployment of cloud based, low cost, product modules.
Engagement of more private and public Australian and New Zealand hospitals.
Development of key partnerships with healthcare technology partners.
The TechKnow Invest Roadshow is the premier investor focused technology event in Australasia, so you will have the opportunity to learn about many other unique technology companies operating in this very innovative space.

Event Details
The TechKnow Invest Roadshow will showcase many unique Australian technology companies to over 700 investors at three venues in Brisbane, Sydney & Melbourne.

Melbourne Event
Date: Tuesday 18th October 2016
Alcidion presenting at 11:40 am
Venue: Grand Hyatt Hotel, Melbourne

Sydney Event
Date: Thursday 20th October 2016Alcidion presenting at 2:30 pm
Venue: Radisson Blu Hotel, Sydney

Brisbane Event
Date: Friday 21st October 2016
Alcidion presenting at 10:05 am
Venue: Brisbane Hilton, Brisbane

Time
All events will open for a 8:15 am arrival and 9:00 am start, conference close will be 3.45 pm.

Registration
Registration is free. Please register on the TechKnow website. Tickets are going fast, so be quick!

Refreshments, morning tea and lunch will be provided.

We look forward to seeing you there.


Announcement URL:
About Alcidion:

Alcidion provides intelligent Health Informatics technology that empowers healthcare professionals with Clinical Decision Support Systems to ensure the highest quality of care for their patients.

Go to Company Profile for: Alcidion

Announcement Contact: [email protected]

Nathan Buzza

Having founded Clinical Middleware provider CommtechWireless in 1992, Nathan grew this business into a successful multinational with ofïŹces in Perth, Sydney, Jacksonville, Hong Kong, Shenzhen, Vejle & London deploying the technology across 8000 locations worldwide. With 25 years’ experience in software, electronics and medical technology, Nathan is recognised as a technology pioneer in the evolution and implementation of specialised medical technology. In 2008 Nathan negotiated the trade sale of CommtechWireless to Amcom Software and continued as GM for 18 months post acquisition. Prior to the acquisition, Buzza was the principal shareholder, CEO and Chief Technologist of the company and was responsible for strategic planning, technology development and administration of the company’s affairs. In 2010, Amcom Software was acquired by USA Mobility (now Spok) for $163.8m. The business was listed by BRW as one of the fastest growing privately held companies in Australia for three consecutive years and the recipient of numerous accolades including: The Telstra Small Business of the Year Award, The Department of Industry & Resources “CY O’Conner Award for Excellence in Engineering” as well as the ATUG “Best Communication Solution”. In 2006, Nathan’s accomplishments were recognised by Ernst & Young, where Nathan was awarded the “Entrepreneur of the Year” as well as the WA IT & Telecommunications Life Time achievement Award for contribution to the IT community. Nathan judged the Innovator of the Year Awards and the Curtin and Cambridge Universities Ignite Programmes in 2010. Prior to Alcidion, Nathan’s Private Equity firms were the second largest shareholder of Azure Healthcare (ASX:AZV) and during Nathan’s tenure, the company share price increased 1200%. Nathan is a member of the NiQ Healthcare Advisory Board and a General Partner in Private Equity Firm, Future Health. Nathan studied a Bachelor of Commerce at Curtin University, majoring in IT.

Leave a Reply